BioCentury
ARTICLE | Clinical News

CM-24: Ph I terminated

March 29, 2017 12:56 AM UTC

Merck terminated an open-label, dose-escalation, U.S. and Israeli Phase I trial evaluating CM-24 in combination with Keytruda pembrolizumab in 27 patients. The company said CM-24 showed no signs of ef...